Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hurtig forskning i diagnostisk udvikling til TB-netværk (R2D2TB Network)

4. november 2026 opdateret af: University of California, San Francisco

Hurtig forskning i diagnostisk udvikling til TB-netværk (R2D2 TB-netværk).

To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study seeks to identify and rigorously assess promising early stage tuberculosis (TB) triage, diagnostic and drug resistance tests (hereafter referred to as "novel tests") in clinical studies conducted in settings of intended use. Rapid diagnosis, identification of drug resistance and effective treatment are critical for improving patient outcomes and reducing TB transmission. However, analysis of care cascades and prevalence surveys indicate that 40-60% of patients with TB are not initiated on effective treatment.1,2 The different types of tests required to reduce this "diagnostic gap" have been described in the form of target product profiles (TPPs). The highest- priority TPPs are for: 1) a point-of-care, non-sputum biomarker-based test to facilitate rapid TB diagnosis using easily accessible samples (a biomarker-based diagnostic test) and 2) a simple, low-cost test that can be used by front-line health workers to rule-out TB (a triage test). The R2D2 TB Network study will evaluate the sensitivity and specificity of novel triage and diagnostic tests against a reference standard including sputum Xpert® MTB/RIF (Mycobacterium tuberculosis/Rifampin) Ultra and sputum mycobacterial culture. The sensitivity and specificity of rapid drug susceptibility tests (rDST) will be compared against a reference standard including culture-based phenotypic DST and whole genome sequencing (WGS) of mycobacterial DNA. In addition, the usability of novel tests will be assessed through direct observations and surveys of routine health workers.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

26436

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Dasmariñas, Filippinerne
        • Rekruttering
        • De La Salle Medical and Health Sciences Institute
        • Kontakt:
      • Vellore, Indien
        • Rekruttering
        • Chitoor (Christian Medical College satellite campus)
        • Kontakt:
      • Vellore, Indien
        • Rekruttering
        • Christian Medical College CMC Pulmonary Outpatient Department
        • Kontakt:
      • Vellore, Indien
      • Cape Town, Sydafrika
        • Rekruttering
        • Brooklyn Chest Hospital
        • Kontakt:
      • Cape Town, Sydafrika
        • Rekruttering
        • Khayelitsha District Health Center
        • Kontakt:
      • Cape Town, Sydafrika
        • Rekruttering
        • Scottsdene primary care clinic
        • Kontakt:
      • Cape Town, Sydafrika
        • Rekruttering
        • Wallacedene primary care clinic
        • Kontakt:
      • Cape Town, Sydafrika
        • Rekruttering
        • Kraaifontein Community Health Clinic
        • Kontakt:
      • Kampala, Uganda
      • Kampala, Uganda
        • Rekruttering
        • Mulago Outpatient Department
        • Kontakt:
      • Hanoi, Vietnam
        • Rekruttering
        • Hanoi Lung Hospital, Outpatient departments
        • Kontakt:
      • Hanoi, Vietnam
        • Rekruttering
        • National Lung Hospital, Outpatient departments
        • Kontakt:
      • Lusaka, Zambia
        • Rekruttering
        • Centre for Infectious Disease Research in Zambia
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Novel TB triage and diagnostic tests:

We will include non-hospitalized adults (age ≥ 12 years) with either 1) cough ≥2 weeks' duration, a commonly accepted criterion for identifying people with presumed pulmonary TB (to facilitate standardization across sites and comparison of test performance across sub-groups or 2) risk factors for which TB screening is recommended (HIV infection, self-reported close contact, history of mining work). People with risk factors will be included if they screen positive for TB based on WHO-recommended screening tools as specified below:

Positive TB screening definitions by risk factor:

  1. PLHIV (Risk Factor), CRP >5 mg/dL OR abnormal CXR (Positive TB screening definition)
  2. Self-reported Close Contact (Risk Factor), abnormal CXR (Positive TB screening definition)
  3. History of mining work (Risk Factor), abnormal CXR (Positive TB screening definition)

We will exclude people who:

  1. completed latent or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);
  2. have taken any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason, within 2 weeks of study entry (to reduce false-negatives);
  3. reside >20km from the study site or are unwilling to return for follow-up visits; or
  4. are unwilling to provide informed consent

Novel TB rDST assays:

We will include adults (age ≥12 years) who are positive for TB and RIF resistance according to routine diagnostic testing (based typically on Xpert MTB/RIF, Xpert MTB/RIF Ultra, or Hain MTBDRplus). We will exclude people who:

  1. have negative or contaminated results on all baseline (i.e., enrollment) sputum cultures
  2. are unable to provide at least two sputum specimens of 3 mL each within one day of enrollment
  3. are unable or unwilling to provide informed consent

Assessment of the usability of novel TB tests:

We will include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). We will exclude staff who are unwilling to provide informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Evaluation of various novel TB triage and diagnostic tests.

For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.

We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.

We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.

We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.

We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.

We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).

We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.

Eksperimentel: Evaluation of novel rDST assays

Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate targeted and whole genome sequencing assays.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sensitivity
Tidsramme: 7 months

Number of positive results for a given index test/(Total positive + negative results for a given index test) among patients with TB using the microbiological reference standard

7 months
Specificity
Tidsramme: 7 months

Number of negative results for a given index test/(Total positive + negative results for a given index test) among patients without TB using the microbiological reference standard

7 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Adithya Cattamanchi, MD, University of California, San Francisco

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. april 2021

Primær færdiggørelse (Anslået)

31. maj 2031

Studieafslutning (Anslået)

31. maj 2031

Datoer for studieregistrering

Først indsendt

7. juni 2021

Først indsendt, der opfyldte QC-kriterier

7. juni 2021

Først opslået (Faktiske)

11. juni 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • U01AI152087 (U.S. NIH-bevilling/kontrakt)
  • R01AI190419 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Studiedata/dokumenter

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .